The current state of peptide drug discovery: back to the future?
A Henninot, JC Collins, JM Nuss - Journal of medicinal chemistry, 2018 - ACS Publications
Over the past decade, peptide drug discovery has experienced a revival of interest and
scientific momentum, as the pharmaceutical industry has come to appreciate the role that …
scientific momentum, as the pharmaceutical industry has come to appreciate the role that …
Mechanisms of ketamine action as an antidepressant
Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …
Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments
The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …
related disorders remain unclear, but studies in depressed patients and rodent models are …
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Chronic stress and depressive-like behaviors in basic neuroscience research have been
associated with impairments of neuroplasticity, such as neuronal atrophy and synaptic loss …
associated with impairments of neuroplasticity, such as neuronal atrophy and synaptic loss …
The organization of the stress system and its dysregulation in depressive illness
PW Gold - Molecular psychiatry, 2015 - nature.com
Stressors are imminent or perceived challenges to homeostasis. The stress response is an
innate, stereotypic, adaptive response to stressors that has evolved in the service of …
innate, stereotypic, adaptive response to stressors that has evolved in the service of …
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
K Hashimoto - Psychiatry and clinical neurosciences, 2019 - Wiley Online Library
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …
Approximately one‐third of the patients with MDD are treatment resistant to the current …
Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants
The pathophysiology and treatment of depression have been the focus of intense research
and while there is much that remains unknown, modern neurobiological approaches are …
and while there is much that remains unknown, modern neurobiological approaches are …
Targeting glutamate signalling in depression: progress and prospects
Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
Glutamatergic mechanisms associated with seizures and epilepsy
M Barker-Haliski, HS White - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
Epilepsy is broadly characterized by aberrant neuronal excitability. Glutamate is the
predominant excitatory neurotransmitter in the adult mammalian brain; thus, much of past …
predominant excitatory neurotransmitter in the adult mammalian brain; thus, much of past …
A brief history of the development of antidepressant drugs: from monoamines to glutamate.
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that
is the most common mood disorder in the United States. It has been almost 50 years since …
is the most common mood disorder in the United States. It has been almost 50 years since …